维普中文期刊产品整合服务
14篇 您的检索式:作者名="Warren EJ"
    题名 作者 年代 出处 被引量
1Inci-dence of cardiovascular disease in individuals with psoria-sis :a systematic review and meta-analysis 显示文摘Samarasekera EJ Neilson JM Warren RB 2013J InvestDermatol2013,133,10:1
2Incidence of cardiovascular disease in individuals with psoriasis: A systematie review and meta-analysis显示文摘Samarasekera EJ Neilson JM Warren RB et at 2013J Invest Dermatol2013,133,10:1
3Effects of concen- tric and eccentric training on muscle strength,cross-sectional area,and neural activation显示文摘Higbie EJ Cureton KJ Warren GL 1996J Appl Physiol(1985)1996,81,5:1
4Intrinsic light responses ofretinal ganglion cells projecting to the circadian system显示文摘Warren EJ Allen CN Brown RL 2003Eur JNeurosci2003,17,9:1
5Pericardial effusion and cardiac tamponade in neonates: sudden unexpected death associated with total parenteral nutrition via central venous catheterization 显示文摘Warren M Thompson KS Popek EJ 2013Ann Clin Lab Sci2013,43,2:1
6Review of the safety andefficacy of ustekinumab显示文摘Scherl EJ Kumar S Warren RU 2010Therap Adv Gastroenterol2010,3,:1
7In vitro activity of gemifloxacin (SB 265805) against anaerobes显示文摘Goldstein EJ Citron DM Warren Y 1999Antimicrob Agents Chemother1999,43,:1
8Temporal patterns of plantar pressures and lower-leg muscle activity during walking:effect of speed显示文摘Warren GL Maher RM Higbie EJ 0,,01:1
9Temporal patterns of plantar pressures and lower-leg muscle activity during walking:effect of speed显示文摘Warren GL Maher RM Higbie EJ 2004Gait Posture2004,19,1:1
10In vitro activity of moxifoxacin against 923 anaerobes isolated from human intraabdominal infections显示文摘Goldstein EJ Citron DM Warren YA 2006Antimicrob Agents Chemother2006,50,2:1
11Flumazenil:a benzodiazepine antagonist显示文摘Hoffman EJ Warren EW 1993Clin Pharm1993,12,9:1
12Temporal patterns of plantar pressures and lower-leg muscle activity during walking:effect of speed显示文摘Warren GL Maher RM Higbie EJ 2004Gait andPosture2004,19,:1
13Novel mutations in the carbohydrate sulfotransferase gene (CHST6) in American patients with macular corneal dystrophy显示文摘Aldave AJ Yellore VS Thonar EJ Udar N Warren JF Yoon MK 2004Am J Ophthalmol2004,137,3:1
14生物制剂治疗银屑病患者出现严重感染的风险评估:一项系统性回顾与荟萃分析显示文摘肿瘤坏死因子抑制剂英夫利昔单抗、依那西普和阿达木单抗是目前用于治疗银屑病常用的3种生物制剂,新药优特克单抗是IL-12和IL-23拮抗剂,苏金单抗是IL-17受体拮抗剂。生物制剂通过抑制细胞因子,调控银屑病患者紊乱的免疫系统,从而发挥疗效。肿瘤坏死因子等细胞因子在细胞感染免疫应答和肉芽肿形成过程中是不可或缺的重要一员,因此生物治疗是否存在引起严重感染的风险是临床医师非常关注的问题。目前缺乏对生物制剂治疗银屑病引起严重感染风险的综合评估。Yiu ZZ Exton LS Jabbar-Lopez Z Mohd Mustapa MF Samarasekera EJ Burden AD Murphy R Owen CM Parslew R Venning V Ashcroft DM Griffiths CE Smith CH Warren RB 薛如君 张锡宝 2017皮肤性病诊疗学杂志2017,24,3:0
返回顶部 每页显示:
共1页 首页 上一页 第1页 下一页 末页 /1 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费